Zacks: Brokerages Anticipate Omeros Co. (NASDAQ:OMER) to Announce -$0.48 Earnings Per Share

Wall Street brokerages expect that Omeros Co. (NASDAQ:OMER) will post earnings per share (EPS) of ($0.48) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Omeros’ earnings. The lowest EPS estimate is ($0.50) and the highest is ($0.46). Omeros reported earnings per share of ($0.34) during the same quarter last year, which would suggest a negative year-over-year growth rate of 41.2%. The company is expected to report its next quarterly earnings report on Monday, November 8th.

On average, analysts expect that Omeros will report full-year earnings of ($1.98) per share for the current financial year, with EPS estimates ranging from ($2.06) to ($1.93). For the next year, analysts expect that the firm will post earnings of ($1.44) per share, with EPS estimates ranging from ($1.62) to ($1.28). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that cover Omeros.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Sunday, August 8th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.04. The firm had revenue of $28.82 million for the quarter, compared to analyst estimates of $25.95 million.

Several analysts have recently commented on the company. Zacks Investment Research downgraded Omeros from a “buy” rating to a “hold” rating in a research note on Friday, September 10th. WBB Securities increased their price objective on Omeros from $75.00 to $100.00 and gave the stock a “strong-buy” rating in a research note on Friday, June 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of Omeros in a report on Tuesday, September 7th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to data from, the company has an average rating of “Buy” and an average price target of $36.67.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Capital Analysts LLC purchased a new stake in shares of Omeros in the first quarter worth $36,000. Dark Forest Capital Management LP purchased a new stake in Omeros during the second quarter valued at about $41,000. Wolverine Asset Management LLC purchased a new stake in Omeros during the first quarter valued at about $89,000. Quantbot Technologies LP raised its position in Omeros by 363.3% during the first quarter. Quantbot Technologies LP now owns 5,078 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 3,982 shares in the last quarter. Finally, Advisor Group Holdings Inc. raised its position in Omeros by 982.8% during the second quarter. Advisor Group Holdings Inc. now owns 6,280 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 5,700 shares in the last quarter. 51.84% of the stock is owned by institutional investors and hedge funds.

Shares of Omeros stock opened at $15.76 on Tuesday. The company has a market cap of $984.94 million, a PE ratio of -6.88 and a beta of 1.12. Omeros has a 52 week low of $9.25 and a 52 week high of $23.85. The business has a 50 day moving average price of $14.96 and a 200-day moving average price of $16.45.

About Omeros

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

Recommended Story: The components of the Stochastic Momentum Index

Get a free copy of the Zacks research report on Omeros (OMER)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with's FREE daily email newsletter.